

COVID-19 Vaccine Effectiveness by Product and Timing in New York State

Eli S. Rosenberg PhD^{1,2}, Vajeera Dorabawila PhD¹, Delia Easton PhD¹, Ursula Bauer PhD¹, Jessica Kumar DO¹, Rebecca Hoen DrPH¹, Dina Hoefer PhD¹, Meng Wu PhD¹, Emily Lutterloh MD^{1,2}, Mary Beth Conroy MPH¹, Danielle Greene DrPH¹, Howard A. Zucker MD¹

1. New York State Department of Health, Albany, New York
2. University at Albany School of Public Health, State University of New York, Rensselaer, New York.

Supplementary Appendix

Contents

Supplementary Methods	2
Figure S1: Weekly hazard rates for Laboratory-confirmed COVID-19 cases by Vaccine Product, Age, and Timing of Vaccination.....	3
Figure S2: Monthly incidence rates for laboratory-confirmed COVID-19 hospitalization by Vaccine Product, Age, and Timing of Vaccination.....	4
Table S1: Overview of phased vaccine eligibility in New York State	5
Table S2: Estimated vaccine effectiveness for laboratory-confirmed COVID-19 cases, adjusted for census uncertainty (sensitivity analysis #1)	8
Table S3: Estimated vaccine effectiveness for laboratory-confirmed COVID-19 cases, using the entire unvaccinated population size (sensitivity analysis #2)	9
Table S4: Estimated vaccine effectiveness for laboratory-confirmed COVID-19 hospitalizations, adjusted for census uncertainty (sensitivity analysis #1)	10
Table S5: Estimated vaccine effectiveness for laboratory-confirmed COVID-19 hospitalizations, using the entire unvaccinated population size (sensitivity analysis #2)	11
Table S6: Estimated vaccine effectiveness for laboratory-confirmed COVID-19 hospitalizations, limiting to hospitalizations reported 'for COVID-19' (sensitivity analysis #3) ¹	12
Table S7: Estimated vaccine effectiveness for laboratory-confirmed COVID-19 hospitalizations, using entire time-defined cohorts, without 90-day prior diagnosis exclusion applied (sensitivity analysis #4)	13

Supplementary Methods


Primary and sensitivity analyses

In the primary analysis, persons with a positive laboratory result within 90 days before May 1 were considered not susceptible for either outcome and excluded, per the CDC case-definition. Sensitivity analyses probed the impact of variations in the cohort definitions.


1. The primary analysis used the 2018 Vintage Census file for defining the unvaccinated population, consistent with previous COVID-19 surveillance practice. The intercensal estimates for 2020 projected a 0.8% decrease in the NYS adult population relative to 2018, however the Decennial 2020 estimates projected a 3.9% increase, although age-specific estimates are unavailable.³¹ To assess the potential impact of these added persons on the calculated unvaccinated population size, we distributed the estimated additional 606,000 adults to each age group, proportional to their 2018 representation.
2. Cases within 90 days of May 1 unmatched with the immunization registry were classified unvaccinated; a false non-match could potentially deflate the unvaccinated population. This analysis did not exclude unvaccinated persons with cases within 90 days.
3. About half of hospitalized patients in HERDS were reported admitted “for COVID-19”, using non-standardized definitions.¹⁰ The hospitalization analysis was repeated restricted to such hospitalizations, as opposed to those “with COVID-19” in the primary analysis.
4. The primary analysis defined the susceptible population size identically for both cases and hospitalizations, using a case-based definition. Because no such susceptibility definition exists for hospitalizations, the hospitalization analyses were repeated for the entire time-defined cohort sizes without exclusions applied.

Figure S1: Weekly hazard rates for Laboratory-confirmed COVID-19 cases by Vaccine Product, Age, and Timing of Vaccination


A. Pfizer-BioNTech, 18-49 years




B. Moderna, 18-49 years




C. Janssen, 18-49 years




D. Pfizer-BioNTech, 50-64 years




E. Moderna, 50-64 years




F. Janssen, 50-64 years



G. Pfizer-BioNTech, >=65 years



H. Moderna, >=65 years



I. Janssen, >=65 years






Figure S2: Monthly incidence rates for laboratory-confirmed COVID-19 hospitalization by Vaccine Product, Age, and Timing of Vaccination


A. Pfizer-BioNTech, 18-49 years




B. Moderna, 18-49 years




C. Janssen, 18-49 years




D. Pfizer-BioNTech, 50-64 years




E. Moderna, 50-64 years




F. Janssen, 50-64 years



G. Pfizer-BioNTech, >=65 years



H. Moderna, >=65 years



I. Janssen, >=65 years




Table S1: Overview of phased vaccine eligibility in New York State

Effective Date	Eligible Population
December 14, 2020	High-risk hospital staff, affiliates, volunteers and contract staff, following the clinical risk assessment guidance
December 21, 2020	<ul style="list-style-type: none"> - High-risk hospital staff including State-operated OMH psychiatric centers - Emergency Medical Services (EMS) Personnel - Medical Examiners and Coroners - Funeral workers who have direct contact with infectious material and bodily fluids - Health care or other high-risk direct care essential staff working in LTCFs and long-term, congregate settings overseen by OPWDD, OMH and OASAS - Persons living in LTCFs and in long-term congregate settings overseen by OPWDD and OMH
December 28, 2020	<ul style="list-style-type: none"> - High-risk hospital and FQHC staff, including OMH psychiatric centers - Emergency Medical Services (EMS) Personnel - Medical Examiners and Coroners - Agency staff and residents in congregate living situations run by the Office of People with Developmental Disabilities (OPWDD) the Office of Mental Health (OMH) and the Office of Addiction Services and Supports (OASAS). - Urgent Care providers - Any staff administering COVID-19 Vaccinations
January 4, 2021	<ul style="list-style-type: none"> - All Outpatient/Ambulatory front line, high risk health care providers who provide direct in-person patient care or other staff in a position where they have direct contact with patients, such as receptionists, of any age. - All front line, high risk public health workers who have direct contact with patients, including those conducting COVID-19 Tests
January 12, 2021	<ul style="list-style-type: none"> - Age 65 and older - First Responder or Support Staff for First Responder Agency <ul style="list-style-type: none"> o Fire <ul style="list-style-type: none"> - State Fire Service, including firefighters and investigators (professional and volunteer) o Local Fire Service, including firefighters and investigators (professional and volunteer) <ul style="list-style-type: none"> - Police and Investigations - State Police, including Troopers - State Park Police, DEC Police, Forest Rangers - SUNY Police - Sheriffs' Offices - County Police Departments and Police Districts - City, Town, and Village Police Departments - Transit of other Public Authority Police Departments

Effective Date	Eligible Population
January 12, 2021 <i>continued</i>	<ul style="list-style-type: none"> - State Field Investigations, including DMV, SCOC, Justice Center, DFS, IG, Tax, OCFS, SLA <ul style="list-style-type: none"> o Public Safety Communications <ul style="list-style-type: none"> - Emergency Communication and PSAP Personnel, including dispatchers and technicians o Other Sworn and Civilian Personnel <ul style="list-style-type: none"> - Court Officer - Other Police or Peace Officer - Support or Civilian Staff for Any of the Above Services, Agencies, or Facilities - Corrections <ul style="list-style-type: none"> o State DOCCS Personnel, including correction and parole officers o Local Correctional Facilities, including correction officers o Local Probation Departments, including probation officers o State Juvenile Detention and Rehabilitation Facilities o Local Juvenile Detention and Rehabilitation Facilities - P-12 Schools <ul style="list-style-type: none"> o P-12 school (public or non-public) or school district faculty or staff (includes all teachers, substitute teachers, student teachers, school administrators, paraprofessional staff, and support staff including bus drivers) o Contractor working in a P-12 school (public or non-public) or school district (including contracted bus drivers) o Licensed, registered, approved or legally exempt group childcare - In-Person College Faculty and Instructors - Employees or Support Staff of Licensed, Registered, Approved or Legally Exempt Group Childcare Settings - Licensed, Registered, approved or legally exempt group Childcare Provider - Public Transit <ul style="list-style-type: none"> o Airline and airport employee o Passenger railroad employee o Subway and mass transit employee (i.e., MTA, LIRR, Metro North, NYC Transit, Upstate transit) o Ferry employee o Port Authority employee o Public bus employee - Public Facing Grocery Store Workers - Individual living in a homeless shelter where sleeping, bathing or eating accommodations must be shared with individuals and families who are not part of your household. - Individual working (paid or unpaid) in a homeless shelter where sleeping, bathing or eating accommodations must be shared by individuals and families who are not part of the same household, in a position where there is potential for interaction with shelter residents.

Effective Date	Eligible Population
February 8, 2021	<ul style="list-style-type: none"> - Restaurant employees, - Restaurant delivery workers, and - For-hire vehicle drivers, including taxi, livery, black car, and transportation network company drivers
February 15, 2021	<p>Individuals with comorbidities and underlying conditions are eligible to receive COVID-19 vaccine. The list is subject to change as additional scientific evidence is published and as New York State obtains and analyzes additional state-specific data. Adults over the age of 16 with the following conditions due to increased risk of moderate or severe illness or death from the virus that causes COVID-19 are eligible:</p> <ul style="list-style-type: none"> • Cancer (current or in remission, including 9/11-related cancers); • Chronic kidney disease; • Pulmonary Disease, including but not limited to, COPD (chronic obstructive pulmonary disease), asthma (moderate-to-severe), pulmonary fibrosis, cystic fibrosis, and 9/11 related pulmonary diseases; • Intellectual and Developmental Disabilities including Down Syndrome; • Heart conditions, including but not limited to heart failure, coronary artery disease, cardiomyopathies, or hypertension (high blood pressure); • Immunocompromised state (weakened immune system) including but not limited to solid organ transplant or from blood or bone marrow transplant, immune deficiencies, HIV, use of corticosteroids, use of other immune weakening medicines, or other causes; • Severe Obesity (BMI 40 kg/m²), Obesity (body mass index [BMI] of 30 kg/m² or higher but < 40 kg/m²); • Pregnancy; • Sickle cell disease or Thalassemia; • Type 1 or 2 diabetes mellitus; • Cerebrovascular disease (affects blood vessels and blood supply to the brain); • Neurologic conditions, including but not limited to Alzheimer's Disease or dementia; and • Liver disease.
March 1, 2021	<ul style="list-style-type: none"> - Public-facing hotel workers.
March 17, 2021	<ul style="list-style-type: none"> - Public-facing government and public employees, - Not-for-profit workers who provide public-facing services to New Yorkers in need, and - Essential in-person public-facing building service workers and providers of essential building services.
March 23, 2021	<ul style="list-style-type: none"> - New York Residents age 50 and older.
March 30, 2021	<ul style="list-style-type: none"> - New York Residents age 30 to 50.
April 6, 2021	<ul style="list-style-type: none"> - All New York State residents age 16 and older, including individuals studying in New York, or individuals employed in the State of New York
May 6, 2021	<ul style="list-style-type: none"> - All individuals 16 years of age and older that reside in the United States
May 13, 2021	<ul style="list-style-type: none"> - All individuals 12 years of age and older that reside in the United States

Table S2: Estimated vaccine effectiveness for laboratory-confirmed COVID-19 cases, adjusted for census uncertainty (sensitivity analysis #1)

Vaccine cohort	May 1 week % VE (95% CI)	July 10 week % VE (95% CI)	August 28 week % VE (95% CI)
18-49 years			
Pfizer-BioNTech	92.5 (91.3, 93.7)	59.9 (55.6, 64.3)	63.5 (61.6, 65.4)
January/February	88.8 (85.9, 91.8)	58.0 (49.5, 66.6)	61.6 (57.8, 65.3)
March	89.3 (85.8, 92.7)	58.5 (48.2, 68.8)	60.2 (55.5, 64.8)
April	94.9 (93.6, 96.1)	61.1 (55.7, 66.4)	65.2 (62.9, 67.4)
Moderna	95.9 (94.9, 96.8)	73.2 (69.3, 77.1)	74.6 (72.9, 76.3)
January/February	93.0 (90.8, 95.2)	76.3 (70.1, 82.4)	67.1 (63.8, 70.4)
March	97.5 (95.9, 99.0)	70.6 (62.5, 78.7)	75.4 (72.1, 78.8)
April	97.3 (96.0, 98.5)	72.3 (66.3, 78.3)	80.1 (77.8, 82.4)
Janssen	87.6 (84.7, 90.4)	43.4 (34.1, 52.6)	64.9 (61.6, 68.2)
March	88.6 (82.4, 94.8)	5.9 (0.0, 32.8)	60.2 (52.3, 68.2)
April	87.3 (84.2, 90.5)	52.1 (42.7, 61.5)	66.0 (62.4, 69.6)
50-64 years			
Pfizer-BioNTech	94.5 (93.4, 95.6)	66.6 (60.8, 72.4)	72.0 (69.9, 74.1)
January/February	87.9 (83.9, 91.9)	65.5 (52.8, 78.3)	68.7 (63.9, 73.5)
March	92.3 (89.1, 95.5)	66.7 (54.2, 79.2)	69.6 (64.9, 74.3)
April	96.6 (95.6, 97.7)	66.8 (60.1, 73.6)	73.4 (71.1, 75.7)
Moderna	96.9 (96.0, 97.9)	83.4 (79.0, 87.7)	79.9 (78.0, 81.8)
January/February	95.4 (93.1, 97.8)	74.1 (63.6, 84.5)	72.3 (68.0, 76.5)
March	96.6 (94.4, 98.8)	80.7 (70.8, 90.7)	74.3 (69.8, 78.9)
April	97.7 (96.6, 98.8)	88.4 (83.8, 93.1)	85.4 (83.3, 87.5)
Janssen	84.5 (80.6, 88.5)	67.9 (57.1, 78.6)	71.7 (67.7, 75.7)
March	86.5 (79.8, 93.1)	71.1 (52.9, 89.2)	65.1 (57.2, 73.0)
April	83.7 (78.8, 88.5)	66.5 (53.4, 79.5)	74.6 (70.1, 79.0)
≥65 years			
Pfizer-BioNTech	90.5 (88.9, 92.0)	75.6 (70.1, 81.0)	73.8 (71.7, 76.0)
January/February	82.6 (78.2, 86.9)	67.3 (55.4, 79.3)	71.7 (67.4, 75.9)
March	90.4 (87.9, 92.8)	77.7 (70.1, 85.3)	73.2 (69.9, 76.4)
April	94.3 (92.6, 96.0)	77.8 (70.8, 84.7)	75.4 (72.6, 78.2)
Moderna	95.5 (94.5, 96.5)	84.9 (81.0, 88.9)	81.5 (79.8, 83.2)
January/February	96.7 (94.6, 98.9)	76.5 (65.0, 88.1)	75.4 (70.8, 79.9)
March	95.4 (93.9, 96.9)	83.9 (78.2, 89.7)	81.8 (79.4, 84.1)
April	95.2 (93.7, 96.8)	88.7 (84.0, 93.4)	83.3 (81.1, 85.5)
Janssen	78.6 (72.3, 84.9)	75.7 (62.6, 88.8)	65.7 (59.7, 71.7)
March	83.0 (74.6, 91.4)	83.8 (67.8, 99.8)	61.2 (51.6, 70.8)
April	75.3 (66.4, 84.1)	69.6 (50.3, 88.9)	69.1 (61.7, 76.5)

Table S3: Estimated vaccine effectiveness for laboratory-confirmed COVID-19 cases, using the entire unvaccinated population size (sensitivity analysis #2)

Vaccine cohort	May 1 week % VE (95% CI)	July 10 week % VE (95% CI)	August 28 week % VE (95% CI)
18-49 years			
Pfizer-BioNTech	93.1 (92.0, 94.2)	63.2 (59.2, 67.2)	66.5 (64.8, 68.3)
January/February	89.7 (87.1, 92.4)	61.4 (53.6, 69.3)	64.8 (61.4, 68.2)
March	90.1 (86.9, 93.3)	61.9 (52.4, 71.4)	63.5 (59.2, 67.7)
April	95.3 (94.1, 96.4)	64.2 (59.3, 69.1)	68.1 (65.9, 70.2)
Moderna	96.2 (95.3, 97.1)	75.4 (71.8, 79.0)	76.7 (75.1, 78.3)
January/February	93.5 (91.5, 95.6)	78.2 (72.6, 83.8)	69.9 (66.8, 72.9)
March	97.7 (96.2, 99.1)	73.0 (65.6, 80.4)	77.5 (74.4, 80.6)
April	97.5 (96.3, 98.6)	74.5 (69.1, 80.0)	81.8 (79.7, 83.9)
Janssen	88.6 (86.0, 91.2)	48.0 (39.5, 56.5)	67.8 (64.8, 70.8)
March	89.5 (83.8, 95.2)	13.5 (0.0, 38.3)	63.5 (56.2, 70.8)
April	88.3 (85.4, 91.3)	56.0 (47.4, 64.6)	68.8 (65.5, 72.1)
50-64 years			
Pfizer-BioNTech	94.9 (93.9, 95.9)	69.1 (63.7, 74.5)	74.2 (72.3, 76.1)
January/February	88.8 (85.1, 92.5)	68.1 (56.3, 79.9)	71.1 (66.7, 75.5)
March	92.9 (89.9, 95.8)	69.2 (57.6, 80.8)	71.9 (67.6, 76.3)
April	96.9 (95.9, 97.8)	69.3 (63.1, 75.6)	75.5 (73.3, 77.6)
Moderna	97.2 (96.3, 98.0)	84.6 (80.6, 88.6)	81.5 (79.7, 83.2)
January/February	95.8 (93.6, 97.9)	76.0 (66.3, 85.7)	74.4 (70.4, 78.3)
March	96.9 (94.8, 98.9)	82.2 (73.0, 91.4)	76.3 (72.1, 80.5)
April	97.9 (96.9, 98.9)	89.3 (85.0, 93.6)	86.5 (84.6, 88.4)
Janssen	85.7 (82.0, 89.3)	70.3 (60.3, 80.3)	73.9 (70.2, 77.6)
March	87.5 (81.3, 93.7)	73.3 (56.5, 90.0)	67.8 (60.5, 75.1)
April	84.9 (80.4, 89.4)	69.0 (57.0, 81.1)	76.5 (72.4, 80.6)
≥65 years			
Pfizer-BioNTech	91.2 (89.8, 92.6)	77.5 (72.5, 82.5)	75.9 (73.9, 77.9)
January/February	83.9 (79.9, 87.9)	69.9 (58.8, 80.9)	73.9 (70.0, 77.8)
March	91.1 (88.9, 93.4)	79.4 (72.4, 86.4)	75.3 (72.3, 78.3)
April	94.7 (93.2, 96.3)	79.5 (73.1, 85.9)	77.3 (74.7, 79.9)
Moderna	95.9 (95.0, 96.8)	86.1 (82.5, 89.7)	83.0 (81.4, 84.6)
January/February	97.0 (95.0, 99.0)	78.4 (67.7, 89.0)	77.3 (73.1, 81.5)
March	95.8 (94.4, 97.1)	85.2 (79.9, 90.5)	83.2 (81.0, 85.4)
April	95.6 (94.2, 97.0)	89.6 (85.3, 93.9)	84.6 (82.6, 86.7)
Janssen	80.2 (74.4, 86.0)	77.6 (65.5, 89.7)	68.4 (62.9, 74.0)
March	84.3 (76.5, 92.1)	85.1 (70.3, 99.8)	64.3 (55.4, 73.1)
April	77.2 (69.0, 85.3)	72.0 (54.2, 89.7)	71.5 (64.7, 78.4)

Table S4: Estimated vaccine effectiveness for laboratory-confirmed COVID-19 hospitalizations, adjusted for census uncertainty (sensitivity analysis #1)

Vaccine cohort	May 2021 % VE (95% CI)	June 2021 % VE (95% CI)	July 2021 % VE (95% CI)	August 2021 % VE (95% CI)
18-49 years				
Pfizer-BioNTech	95.8 (93.6, 97.4)	93.7 (89.2, 96.7)	95.2 (91.8, 97.4)	94.8 (93.0, 96.2)
January/February	97.6 (92.9, 99.5)	98.0 (88.7, 99.9)	95.6 (87.2, 99.1)	91.9 (87.0, 95.3)
March	98.8 (93.3, 100.0)	97.0 (83.3, 99.9)	95.7 (84.4, 99.5)	94.4 (88.9, 97.6)
April	94.2 (90.8, 96.6)	91.2 (84.1, 95.6)	94.8 (90.1, 97.6)	96.0 (93.9, 97.5)
Moderna	96.2 (93.8, 97.9)	90.6 (84.3, 94.8)	95.5 (91.7, 97.8)	97.0 (95.4, 98.2)
January/February	96.3 (91.3, 98.8)	98.1 (89.6, 100.0)	98.7 (92.5, 100.0)	96.9 (93.7, 98.8)
March	97.9 (92.4, 99.7)	89.6 (73.1, 97.2)	90.6 (78.0, 97.0)	97.5 (93.7, 99.3)
April	95.2 (90.6, 97.9)	85.1 (72.4, 92.9)	95.7 (89.0, 98.8)	96.8 (94.0, 98.6)
Janssen	95.2 (90.1, 98.1)	86.4 (72.9, 94.1)	93.9 (85.6, 98.0)	92.8 (88.5, 95.7)
March	89.2 (68.2, 97.8)	45.8 (0.0, 80.2)	93.5 (63.7, 99.8)	91.5 (78.1, 97.7)
April	96.6 (91.4, 99.1)	95.8 (84.7, 99.5)	93.9 (84.4, 98.4)	93.0 (88.3, 96.2)
50-64 years				
Pfizer-BioNTech	95.1 (93.6, 96.4)	94.4 (91.3, 96.5)	92.8 (89.9, 95.1)	94.3 (93.1, 95.3)
January/February	91.9 (86.6, 95.5)	92.2 (81.7, 97.5)	96.3 (89.0, 99.2)	93.7 (90.3, 96.1)
March	93.0 (87.9, 96.3)	95.3 (86.2, 99.0)	90.0 (80.2, 95.7)	95.2 (92.2, 97.3)
April	96.4 (94.8, 97.7)	94.7 (90.9, 97.1)	92.7 (89.0, 95.4)	94.2 (92.7, 95.4)
Moderna	96.9 (95.4, 98.0)	96.5 (93.5, 98.4)	96.1 (93.4, 97.9)	96.4 (95.3, 97.3)
January/February	98.0 (95.0, 99.5)	100.0 (94.8, 100.0)	97.8 (91.8, 99.7)	96.5 (93.9, 98.1)
March	100.0 (97.8, 100.0)	98.3 (90.2, 100.0)	97.2 (89.9, 99.7)	97.6 (95.1, 99.1)
April	95.2 (92.7, 97.0)	94.4 (89.2, 97.4)	95.0 (90.7, 97.6)	95.9 (94.2, 97.2)
Janssen	86.1 (80.5, 90.5)	89.4 (79.7, 95.2)	88.7 (80.1, 94.2)	91.6 (88.4, 94.1)
March	89.1 (78.5, 95.3)	92.2 (71.5, 99.1)	84.3 (63.1, 94.9)	90.9 (84.1, 95.3)
April	84.8 (77.6, 90.1)	88.2 (75.5, 95.3)	90.6 (80.4, 96.2)	91.9 (88.0, 94.8)
≥65 years				
Pfizer-BioNTech	94.1 (93.2, 95.0)	92.8 (90.9, 94.3)	87.8 (85.3, 89.9)	87.4 (86.1, 88.6)
January/February	92.0 (89.6, 94.0)	91.6 (87.1, 94.9)	87.4 (82.0, 91.6)	83.9 (80.9, 86.5)
March	95.1 (93.6, 96.3)	93.1 (90.0, 95.4)	87.1 (83.0, 90.4)	87.8 (85.9, 89.6)
April	94.4 (93.0, 95.5)	93.1 (90.4, 95.2)	88.4 (84.9, 91.3)	88.7 (86.9, 90.2)
Moderna	96.8 (96.1, 97.4)	95.8 (94.5, 96.9)	94.4 (92.8, 95.7)	93.1 (92.2, 93.9)
January/February	97.0 (95.0, 98.3)	95.5 (91.2, 98.1)	90.4 (84.5, 94.4)	92.1 (89.5, 94.1)
March	97.0 (96.0, 97.9)	97.0 (95.1, 98.3)	95.1 (92.8, 96.8)	93.1 (91.8, 94.3)
April	96.4 (95.3, 97.3)	94.7 (92.3, 96.5)	95.0 (92.6, 96.7)	93.3 (92.0, 94.4)
Janssen	83.0 (78.3, 86.9)	77.6 (68.1, 84.9)	79.4 (70.1, 86.4)	79.9 (75.4, 83.7)
March	88.8 (82.4, 93.2)	77.2 (61.4, 87.6)	80.1 (65.0, 89.8)	80.0 (73.0, 85.6)
April	78.7 (71.6, 84.3)	78.0 (64.8, 87.0)	78.9 (65.8, 87.8)	79.8 (73.7, 84.7)

Table S5: Estimated vaccine effectiveness for laboratory-confirmed COVID-19 hospitalizations, using the entire unvaccinated population size (sensitivity analysis #2)

Vaccine cohort	May 2021 % VE (95% CI)	June 2021 % VE (95% CI)	July 2021 % VE (95% CI)	August 2021 % VE (95% CI)
18-49 years				
Pfizer-BioNTech	96.1 (94.1, 97.6)	94.2 (90.1, 97.0)	95.5 (92.5, 97.6)	95.2 (93.6, 96.5)
January/February	97.8 (93.5, 99.5)	98.1 (89.6, 100.0)	96.0 (88.3, 99.2)	92.6 (88.1, 95.7)
March	98.9 (93.9, 100.0)	97.3 (84.6, 99.9)	96.0 (85.7, 99.5)	94.8 (89.8, 97.8)
April	94.7 (91.6, 96.9)	91.9 (85.4, 96.0)	95.2 (90.9, 97.8)	96.3 (94.4, 97.7)
Moderna	96.5 (94.3, 98.1)	91.4 (85.6, 95.2)	95.8 (92.3, 98.0)	97.3 (95.8, 98.3)
January/February	96.6 (92.0, 98.9)	98.3 (90.5, 100.0)	98.8 (93.1, 100.0)	97.2 (94.2, 98.9)
March	98.1 (93.1, 99.8)	90.4 (75.3, 97.4)	91.4 (79.8, 97.2)	97.7 (94.2, 99.4)
April	95.6 (91.3, 98.1)	86.3 (74.6, 93.5)	96.1 (89.9, 98.9)	97.1 (94.5, 98.7)
Janssen	95.6 (90.9, 98.2)	87.5 (75.1, 94.6)	94.4 (86.8, 98.2)	93.3 (89.4, 96.1)
March	90.0 (70.8, 97.9)	50.2 (-9.2, 81.8)	94.0 (66.6, 99.8)	92.2 (79.9, 97.9)
April	96.9 (92.1, 99.2)	96.1 (86.0, 99.5)	94.4 (85.7, 98.5)	93.6 (89.2, 96.5)
50-64 years				
Pfizer-BioNTech	95.5 (94.1, 96.6)	94.8 (92.0, 96.8)	93.4 (90.6, 95.5)	94.7 (93.6, 95.6)
January/February	92.5 (87.6, 95.8)	92.8 (83.0, 97.7)	96.5 (89.8, 99.3)	94.2 (91.0, 96.4)
March	93.5 (88.8, 96.6)	95.7 (87.3, 99.1)	90.8 (81.7, 96.0)	95.5 (92.8, 97.5)
April	96.7 (95.2, 97.8)	95.1 (91.6, 97.3)	93.2 (89.8, 95.7)	94.6 (93.3, 95.8)
Moderna	97.1 (95.7, 98.1)	96.8 (94.0, 98.5)	96.4 (93.9, 98.1)	96.7 (95.6, 97.5)
January/February	98.2 (95.4, 99.5)	100.0 (95.2, 100.0)	97.9 (92.4, 99.7)	96.7 (94.4, 98.3)
March	100.0 (97.9, 100.0)	98.4 (91.0, 100.0)	97.4 (90.6, 99.7)	97.8 (95.5, 99.1)
April	95.6 (93.3, 97.2)	94.8 (90.0, 97.6)	95.4 (91.4, 97.8)	96.2 (94.7, 97.4)
Janssen	87.2 (81.9, 91.2)	90.2 (81.2, 95.6)	89.6 (81.6, 94.7)	92.2 (89.2, 94.5)
March	89.9 (80.1, 95.7)	92.8 (73.6, 99.1)	85.5 (65.9, 95.3)	91.6 (85.3, 95.7)
April	86.0 (79.3, 90.9)	89.1 (77.3, 95.7)	91.3 (81.9, 96.5)	92.5 (88.9, 95.2)
≥65 years				
Pfizer-BioNTech	94.6 (93.7, 95.4)	93.3 (91.6, 94.7)	88.7 (86.4, 90.7)	88.4 (87.2, 89.4)
January/February	92.6 (90.4, 94.5)	92.3 (88.1, 95.3)	88.4 (83.3, 92.2)	85.1 (82.3, 87.5)
March	95.4 (94.1, 96.5)	93.6 (90.8, 95.7)	88.1 (84.3, 91.2)	88.8 (86.9, 90.4)
April	94.8 (93.5, 95.9)	93.6 (91.1, 95.6)	89.3 (86.1, 91.9)	89.5 (87.9, 91.0)
Moderna	97.0 (96.4, 97.6)	96.1 (94.9, 97.1)	94.8 (93.4, 96.0)	93.6 (92.8, 94.3)
January/February	97.2 (95.4, 98.4)	95.9 (91.8, 98.2)	91.1 (85.7, 94.9)	92.7 (90.3, 94.6)
March	97.3 (96.3, 98.0)	97.3 (95.5, 98.4)	95.5 (93.3, 97.1)	93.7 (92.4, 94.7)
April	96.7 (95.7, 97.5)	95.1 (92.9, 96.8)	95.4 (93.2, 97.0)	93.8 (92.6, 94.9)
Janssen	84.3 (80.0, 87.9)	79.4 (70.5, 86.0)	81.0 (72.4, 87.4)	81.4 (77.3, 85.0)
March	89.6 (83.7, 93.8)	78.9 (64.3, 88.6)	81.7 (67.7, 90.6)	81.6 (75.1, 86.7)
April	80.3 (73.7, 85.5)	79.7 (67.5, 88.0)	80.5 (68.5, 88.7)	81.3 (75.8, 85.9)

Table S6: Estimated vaccine effectiveness for laboratory-confirmed COVID-19 hospitalizations, limiting to hospitalizations reported ‘for COVID-19’ (sensitivity analysis #3) ¹

Vaccine cohort	May 2021 % VE (95% CI)	June 2021 % VE (95% CI)	July 2021 % VE (95% CI)	August 2021 % VE (95% CI)
18-49 years				
Pfizer-BioNTech	99.0 (97.8, 99.6)	97.5 (94.6, 99.1)	98.2 (96.1, 99.4)	98.1 (97.0, 98.8)
January/February	100.0 (97.5, 100.0)	100.0 (93.6, 100.0)	97.5 (91.0, 99.7)	96.7 (93.6, 98.6)
March	100.0 (96.2, 100.0)	97.4 (85.7, 99.9)	96.3 (86.7, 99.6)	99.4 (96.6, 100.0)
April	98.4 (96.4, 99.4)	96.6 (92.0, 98.9)	99.0 (96.4, 99.9)	98.2 (96.8, 99.1)
Moderna	98.9 (97.5, 99.7)	97.9 (94.5, 99.4)	97.7 (94.9, 99.2)	99.0 (98.0, 99.6)
January/February	99.4 (96.5, 100.0)	100.0 (94.1, 100.0)	98.9 (93.6, 100.0)	99.3 (97.3, 99.9)
March	99.1 (95.0, 100.0)	95.5 (83.8, 99.5)	93.6 (83.5, 98.3)	98.9 (96.2, 99.9)
April	98.5 (95.5, 99.7)	97.5 (90.8, 99.7)	99.1 (94.9, 100.0)	98.8 (96.9, 99.7)
Janssen	98.3 (94.9, 99.6)	95.6 (87.2, 99.1)	95.8 (89.2, 98.9)	96.2 (93.2, 98.1)
March	96.9 (82.8, 99.9)	84.6 (44.0, 98.1)	94.4 (69.0, 99.9)	98.2 (89.8, 100.0)
April	98.6 (94.8, 99.8)	98.2 (89.9, 100.0)	96.1 (88.6, 99.2)	95.8 (92.2, 98.0)
50-64 years				
Pfizer-BioNTech	98.2 (97.3, 98.8)	99.3 (98.1, 99.9)	96.2 (94.1, 97.6)	97.0 (96.2, 97.7)
January/February	94.9 (90.9, 97.5)	98.7 (92.5, 100.0)	98.9 (94.0, 100.0)	95.6 (93.0, 97.5)
March	97.2 (94.0, 99.0)	100.0 (95.1, 100.0)	93.6 (86.0, 97.7)	97.9 (95.9, 99.1)
April	99.2 (98.4, 99.7)	99.3 (97.6, 99.9)	96.1 (93.5, 97.8)	97.2 (96.2, 97.9)
Moderna	98.9 (98.0, 99.4)	98.8 (96.9, 99.7)	98.8 (97.2, 99.6)	98.6 (97.9, 99.1)
January/February	100.0 (98.5, 100.0)	100.0 (95.5, 100.0)	100.0 (96.4, 100.0)	98.6 (97.0, 99.5)
March	100.0 (98.1, 100.0)	100.0 (94.5, 100.0)	98.8 (93.3, 100.0)	99.1 (97.5, 99.8)
April	98.0 (96.3, 99.0)	97.9 (94.5, 99.4)	98.3 (95.6, 99.5)	98.4 (97.4, 99.1)
Janssen	92.3 (88.3, 95.2)	96.0 (89.6, 98.9)	91.2 (84.0, 95.6)	95.0 (92.6, 96.7)
March	94.2 (86.4, 98.1)	96.7 (81.2, 99.9)	86.6 (68.5, 95.7)	93.5 (88.1, 96.9)
April	91.5 (86.4, 95.1)	95.7 (87.3, 99.1)	93.1 (84.9, 97.5)	95.6 (92.8, 97.5)
≥65 years				
Pfizer-BioNTech	97.7 (97.1, 98.1)	97.9 (97.0, 98.6)	94.7 (93.2, 95.9)	93.4 (92.5, 94.1)
January/February	97.0 (95.6, 98.1)	97.6 (95.1, 99.0)	95.8 (92.7, 97.9)	91.3 (89.2, 93.0)
March	98.0 (97.1, 98.7)	97.2 (95.3, 98.5)	94.6 (92.1, 96.5)	93.2 (91.8, 94.4)
April	97.7 (96.8, 98.4)	98.6 (97.3, 99.3)	94.2 (91.8, 96.0)	94.5 (93.3, 95.4)
Moderna	98.7 (98.3, 99.0)	98.5 (97.7, 99.1)	97.3 (96.3, 98.1)	96.1 (95.5, 96.7)
January/February	98.6 (97.3, 99.4)	98.6 (95.8, 99.7)	94.7 (90.4, 97.4)	95.4 (93.5, 96.8)
March	98.6 (97.9, 99.1)	99.1 (97.9, 99.7)	97.3 (95.6, 98.4)	95.9 (94.9, 96.7)
April	98.8 (98.2, 99.3)	98.0 (96.5, 98.9)	98.3 (96.9, 99.1)	96.6 (95.7, 97.3)
Janssen	91.8 (88.6, 94.2)	91.1 (85.1, 95.0)	90.9 (84.9, 95.0)	89.3 (86.2, 91.8)
March	93.4 (88.7, 96.5)	93.0 (83.7, 97.7)	90.1 (79.5, 96.0)	88.5 (83.4, 92.3)
April	90.5 (85.9, 93.9)	89.5 (80.6, 95.0)	91.5 (83.1, 96.4)	89.9 (85.8, 93.0)

1. The restriction applied in this scenario reduced the number of events observed. Estimates of 100.0% reflect strata in which 0 hospitalizations among fully-vaccinated persons and should be interpreted both with caution and in conjunction with the lower-bound of the exact 95% confidence interval.

Table S7: Estimated vaccine effectiveness for laboratory-confirmed COVID-19 hospitalizations, using entire time-defined cohorts, without 90-day prior diagnosis exclusion applied (sensitivity analysis #4)

Vaccine cohort	May 2021 % VE (95% CI)	June 2021 % VE (95% CI)	July 2021 % VE (95% CI)	August 2021 % VE (95% CI)
18-49 years				
Pfizer-BioNTech	96.1 (94.1, 97.6)	94.3 (90.2, 97.0)	95.6 (92.6, 97.6)	95.2 (93.6, 96.5)
January/February	97.8 (93.5, 99.5)	98.2 (89.7, 100.0)	96.0 (88.3, 99.2)	92.6 (88.1, 95.7)
March	98.9 (93.9, 100.0)	97.3 (84.8, 99.9)	96.1 (85.8, 99.5)	94.9 (89.8, 97.8)
April	94.8 (91.7, 96.9)	92.0 (85.6, 96.0)	95.3 (91.0, 97.9)	96.4 (94.5, 97.8)
Moderna	96.6 (94.3, 98.1)	91.4 (85.7, 95.2)	95.9 (92.4, 98.0)	97.3 (95.8, 98.4)
January/February	96.6 (92.0, 98.9)	98.3 (90.5, 100.0)	98.8 (93.2, 100.0)	97.2 (94.2, 98.9)
March	98.1 (93.1, 99.8)	90.5 (75.4, 97.4)	91.4 (79.9, 97.2)	97.7 (94.2, 99.4)
April	95.7 (91.4, 98.1)	86.5 (74.9, 93.6)	96.1 (90.0, 98.9)	97.1 (94.5, 98.7)
Janssen	95.7 (91.1, 98.3)	87.7 (75.6, 94.7)	94.5 (87.0, 98.2)	93.5 (89.7, 96.1)
March	90.2 (71.3, 98.0)	51.0 (-7.4, 82.1)	94.1 (67.1, 99.9)	92.3 (80.2, 97.9)
April	97.0 (92.2, 99.2)	96.2 (86.2, 99.5)	94.5 (86.0, 98.5)	93.7 (89.5, 96.6)
50-64 years				
Pfizer-BioNTech	95.5 (94.1, 96.7)	94.8 (92.1, 96.8)	93.4 (90.7, 95.5)	94.7 (93.7, 95.7)
January/February	92.6 (87.7, 95.9)	92.9 (83.2, 97.7)	96.6 (89.9, 99.3)	94.2 (91.1, 96.4)
March	93.6 (88.9, 96.6)	95.7 (87.4, 99.1)	90.9 (81.8, 96.1)	95.6 (92.8, 97.5)
April	96.7 (95.2, 97.9)	95.1 (91.7, 97.4)	93.3 (89.9, 95.8)	94.7 (93.3, 95.8)
Moderna	97.1 (95.8, 98.1)	96.8 (94.1, 98.5)	96.4 (93.9, 98.1)	96.7 (95.6, 97.5)
January/February	98.2 (95.4, 99.5)	100.0 (95.2, 100.0)	97.9 (92.4, 99.7)	96.7 (94.4, 98.3)
March	100.0 (97.9, 100.0)	98.4 (91.0, 100.0)	97.4 (90.7, 99.7)	97.8 (95.5, 99.1)
April	95.6 (93.3, 97.3)	94.8 (90.1, 97.7)	95.4 (91.5, 97.8)	96.2 (94.7, 97.4)
Janssen	87.4 (82.2, 91.3)	90.4 (81.5, 95.6)	89.7 (81.9, 94.7)	92.4 (89.4, 94.6)
March	90.1 (80.4, 95.7)	92.8 (74.0, 99.1)	85.7 (66.3, 95.4)	91.7 (85.5, 95.7)
April	86.2 (79.7, 91.1)	89.3 (77.7, 95.7)	91.5 (82.2, 96.6)	92.6 (89.1, 95.2)
≥65 years				
Pfizer-BioNTech	94.6 (93.8, 95.4)	93.4 (91.7, 94.8)	88.8 (86.5, 90.7)	88.4 (87.3, 89.5)
January/February	92.7 (90.4, 94.5)	92.3 (88.1, 95.3)	88.5 (83.5, 92.3)	85.2 (82.5, 87.6)
March	95.5 (94.1, 96.6)	93.6 (90.8, 95.8)	88.2 (84.4, 91.2)	88.8 (87.0, 90.5)
April	94.8 (93.6, 95.9)	93.7 (91.2, 95.6)	89.4 (86.2, 92.0)	89.6 (88.0, 91.0)
Moderna	97.0 (96.4, 97.6)	96.2 (94.9, 97.2)	94.8 (93.4, 96.0)	93.6 (92.8, 94.4)
January/February	97.2 (95.4, 98.4)	95.9 (91.8, 98.2)	91.1 (85.7, 94.9)	92.7 (90.3, 94.6)
March	97.3 (96.3, 98.0)	97.3 (95.5, 98.5)	95.5 (93.3, 97.1)	93.7 (92.4, 94.7)
April	96.7 (95.7, 97.5)	95.1 (92.9, 96.8)	95.4 (93.2, 97.0)	93.8 (92.6, 94.9)
Janssen	84.5 (80.2, 88.1)	79.6 (70.9, 86.2)	81.3 (72.8, 87.6)	81.7 (77.6, 85.2)
March	89.7 (83.9, 93.8)	79.2 (64.7, 88.7)	81.9 (68.0, 90.7)	81.8 (75.3, 86.8)
April	80.6 (74.2, 85.8)	80.0 (68.1, 88.2)	80.8 (69.0, 88.9)	81.6 (76.1, 86.1)